cDNA array-CGH profiling identifies genomic alterations specific to stage and <it>MYCN</it>-amplification in neuroblastoma
<p>Abstract</p> <p>Background</p> <p>Recurrent non-random genomic alterations are the hallmarks of cancer and the characterization of these imbalances is critical to our understanding of tumorigenesis and cancer progression.</p> <p>Results</p> <p>...
Main Authors: | Berthold Frank, Westermann Frank, Son Chang-Gue, Greer Braden T, Krasnoselsky Alexei L, Cenacchi Nicola, Whiteford Craig C, Wei Jun S, Bilke Sven, Chen Qing-Rong, Schwab Manfred, Catchpoole Daniel, Khan Javed |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2004-09-01
|
Series: | BMC Genomics |
Online Access: | http://www.biomedcentral.com/1471-2164/5/70 |
Similar Items
-
MYCN amplification and ATRX mutations are incompatible in neuroblastoma
by: Maged Zeineldin, et al.
Published: (2020-02-01) -
Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma
by: Yan Su, et al.
Published: (2020-11-01) -
Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
by: Michael Hölzel, et al.
Published: (2021-05-01) -
Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by <i>MYCN</i> Amplification
by: Frank Berthold, et al.
Published: (2021-08-01) -
MYCN Function in Neuroblastoma Development
by: Jörg Otte, et al.
Published: (2021-01-01)